Wedbush Reduces Earnings Estimates for Bicara Therapeutics

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Research analysts at Wedbush cut their Q1 2025 earnings estimates for Bicara Therapeutics in a note issued to investors on Thursday, March 27th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.40) for the quarter, down from their previous estimate of ($0.33). Wedbush has a “Outperform” rating and a $31.00 price target on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. Wedbush also issued estimates for Bicara Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.67) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($1.87) EPS and FY2027 earnings at ($2.10) EPS.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08).

Other analysts have also recently issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. HC Wainwright upped their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Bicara Therapeutics has a consensus rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $12.66 on Monday. The stock has a 50 day moving average of $13.07 and a 200 day moving average of $17.76. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC bought a new position in Bicara Therapeutics during the third quarter valued at $1,239,000. FMR LLC purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $57,913,000. Point72 Asset Management L.P. purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $9,474,000. Wellington Management Group LLP bought a new position in Bicara Therapeutics during the 3rd quarter valued at about $19,458,000. Finally, Samsara BioCapital LLC purchased a new stake in Bicara Therapeutics in the 3rd quarter worth about $891,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.